Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RX108 DEB-TACE in primary hepatocellular carcinoma
ChiCTR2100052066Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RX108 in hepatocellular carcinoma (HCC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Oct 2021; status: recruiting.
02
Drugs
RX108
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100052066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052066.